Replimune Group (NASDAQ:REPL) and Sangamo Therapeutics (NASDAQ:SGMO) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, analyst recommendations, profitability, valuation, dividends, institutional ownership and earnings. Institutional & Insider Ownership 55.8% of Replimune Group shares are owned by institutional investors. Comparatively, […]
